To ensure that the ADPKD mouse model could be obtained therapeutic response, we treated Vil‐Cre;Pkd2f3/f3 mice with rapamycin (50 mg/kg/day i.p.)(Protocol I, Fig. 3Aa). This evidence concerns the gene VIL1 and autosomal dominant polycystic kidney disease.